Everest Organics Limited today announced that Remdesivir API has been successfully developed in the R & D facility of Everest Organics Limited.
Commenting on the R&D success of EOL team, Dr. Sirisha Srikakarlapudi, Director, EOL - New Product Development said, "lt's a moment of utmost satisfaction that with hard work of the past few months by Everest Organics R&D team, we have been able to successfully develop Remdesivir API at lab scale in short span of time. The development of Remdesivir API by Everest Organics Limited is the outcome of investments we've made in R&D over the period of the last few years, which further helped strengthening technical expertise. Infact we are poised for development of more products in the Anti-Viral segments in the future".
Shares of EVEREST ORGANICS LTD. was last trading in BSE at Rs.256.1 as compared to the previous close of Rs. 232.85. The total number of shares traded during the day was 41349 in over 625 trades.
The stock hit an intraday high of Rs. 256.1 and intraday low of 223.55. The net turnover during the day was Rs. 10346016.